Drug Discovery Research

Suven discovery research is focused on discovering and developing new chemical entities (NCEs), which are best in class central nervous system therapies for the treatment of cognitive disorders, major depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastro-intestinal motility disorders. Research targets includes serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal (Dopaminergic and seretonergic receptor) and P2X purinoceptor 7 receptor.

CNS Focused Pipeline

Candidates Non-clinical Clinical Phase (US IND) Indication
I II III
Masupirdine

(SUVN-502)
5-HT6 antagonist

Cognition

Alzheimer's Disease

Neuropsychiatric Symptoms

(Alzheimer's Disease)

SUVN-G3031

H3 inverse agonist

Narcolepsy
        Cognitive Disorders
SUVN-D4010

5-HT4 Partial agonist

 

Cognitive Disorders
SUVN-911

Alpha4 Beta2 nAChRs antagonist

Depressive Disorders
SUVN-I6107

M1PAM

Cognitive Disorders
SUVN-M8036

Serotonin/Dopamine

modulator

Psychiatric Disorders
SUVN-D1044

5-HT4 agonist

Gastroinstestinal Disorders

Research Pipeline

Program Devlopment Stage Indication
P2X7 Antagonist Lead Optimization Pain and Inflammation
M4 PAM Hit to Lead Psychosis
5-HT1A Partial Agonist Hit to Lead Treatment Resistant Depression